

## **Supplementary**

**A highly sensitive XNA-based RT-qPCR assay for the identification of ALK, RET, and ROS1 fusions in lung cancer.**

Bongyong Lee\*, Andrew Chern, Andrew Y. Fu, Aiguo Zhang and Michael Y. Sha\*

DiaCarta Inc, 4385 Hopyard Rd., Suite 100, Pleasanton, CA 94588

**\*Corresponding author:** Michael Y. Sha: [msha@diacarta.com](mailto:msha@diacarta.com); Bongyong Lee: [blee@diacarta.com](mailto:blee@diacarta.com)

## **Supplementary Table and Figure Legends**

**Table S1. Amsbio FFPE sample information**

**Table S2. Sequence information of synthetic fusion and wild type templates**

**Table S3. The effect of XNA on fusion detection**

**Figure S1. Schematic of Qfusion™ ALK, RET, or ROS1 fusion detection assay targets.**

**Figure S2. Schematic of RT-qPCR workflow for Qfusion™ ALK, RET, or ROS1 fusion detection assay.**

**Figure S3. XNA blocker principal and PCR cycle**

XNA binds tightly to wild-type sequences with a perfect match at 70°C, effectively blocking DNA polymerase during the elongation step at 64°C. Moreover, XNA can bind to fusion sequences with imperfect matches, allowing DNA polymerase to displace XNA and amplify the target sequences.

**Figure S4. Confirmation of fusion genes by Sanger sequencing.**

Red arrow indicates the breaking point.

**Table S1.** Amsbio FFPE sample information

Sample ID	Catalog #	Patient ID	Pathology Diagnosis	Anatomical Site	Gender	Tissue Specification	Histology Grade	TNM Stage (T)	TNM Stage (N)	TNM Stage (M)	TNM Stage
190431	AMS-28011	AMS001	Adenocarcinoma	Lung	Male	Tumor	G2	T2b	Nx	Mx	IIA
190432	AMS-28011	AMS002	Large Cell Carcinoma	Lung	Male	Tumor	G2	T2b	Nx	Mx	IIA
190433	AMS-28011	AMS003	Adenocarcinoma	Lung	Female	Tumor	G2	T3	Nx	Mx	IIB
190434	AMS-28011	AMS004	Adenocarcinoma	Lung	Male	Tumor	G3	T3	Nx	Mx	IIB
190435	AMS-28011	AMS005	Adenocarcinoma	Lung	Male	Tumor	G2	T2a	Nx	Mx	IB
190436	AMS-28011	AMS006	Adenocarcinoma	Lung	Female	Tumor	G3	T2b	Nx	Mx	IIA
190437	AMS-28011	AMS007	Large Cell Carcinoma	Lung	Male	Tumor	G2	T2b	Nx	Mx	IIA
190438	AMS-28011	AMS008	Adenocarcinoma	Lung	Female	Tumor	G3	T3	Nx	Mx	IIB
190439	AMS-28011	AMS009	Adenocarcinoma	Lung	Female	Tumor	G2	T2a	Nx	Mx	IB
190222	AMS-28011	AMS010	Adenocarcinoma	Lung	Male	Tumor	G2	T2b	Nx	Mx	IIA
191573	AMS-28011	AMS011	Adenocarcinoma	Lung	Male	Tumor	G2	T2b	Nx	Mx	IIA
191574	AMS-28011	AMS012	Adenocarcinoma	Lung	Male	Tumor	G2	T2b	Nx	Mx	IIA
191575	AMS-28011	AMS013	Adenocarcinoma	Lung	Female	Tumor	G2	T2a	Nx	Mx	IB
191576	AMS-28011	AMS014	Large Cell Carcinoma	Lung	Male	Tumor	G3	T2b	Nx	Mx	IIA
191577	AMS-28011	AMS015	Large Cell Carcinoma	Lung	Male	Tumor	G3	T2b	Nx	Mx	IIA
191578	AMS-28011	AMS016	Adenocarcinoma	Lung	Male	Tumor	G2	T2a	Nx	Mx	IB
191579	AMS-28011	AMS017	Adenocarcinoma	Lung	Female	Tumor	G2	T2a	Nx	Mx	IB
191580	AMS-28011	AMS018	Large Cell Carcinoma	Lung	Male	Tumor	G3	T3	Nx	Mx	IIB
191581	AMS-28011	AMS019	Adenocarcinoma	Lung	Female	Tumor	G2	T2a	Nx	Mx	IB
191582	AMS-28011	AMS020	Adenocarcinoma	Lung	Male	Tumor	G3	T2b	Nx	Mx	IIA
191583	AMS-28011	AMS021	Adenocarcinoma	Lung	Female	Tumor	G2	T2a	Nx	Mx	IB
191584	AMS-28011	AMS022	Adenocarcinoma	Lung	Male	Tumor	G2	T1c	Nx	Mx	IA3
191585	AMS-28011	AMS023	Large Cell Carcinoma	Lung	Male	Tumor	G3	T2b	Nx	Mx	IIA
191586	AMS-28011	AMS024	Large Cell Carcinoma	Lung	Male	Tumor	G2	T2b	Nx	Mx	IIA
191587	AMS-28011	AMS025	Adenocarcinoma	Lung	Male	Tumor	G3	T3	Nx	Mx	IIB
191588	AMS-28011	AMS026	Adenocarcinoma	Lung	Female	Tumor	G2	T2b	Nx	Mx	IIA
191589	AMS-28011	AMS027	Adenocarcinoma	Lung	Male	Tumor	G2	T1c	Nx	Mx	IA3
191590	AMS-28011	AMS028	Adenocarcinoma	Lung	Male	Tumor	G2	T2a	Nx	Mx	IB
191591	AMS-28011	AMS029	Adenocarcinoma	Lung	Male	Tumor	G2	T2a	Nx	Mx	IB
191592	AMS-28011	AMS030	Adenocarcinoma	Lung	Male	Tumor	G2	T2a	Nx	Mx	IB
191593	AMS-28011	AMS031	Adenocarcinoma	Lung	Male	Tumor	G3	T2b	Nx	Mx	IIA
191594	AMS-28011	AMS032	Adenocarcinoma	Lung	Male	Tumor	G2	T1c	Nx	Mx	IA3
191595	AMS-28011	AMS033	Adenocarcinoma	Lung	Female	Tumor	G2	T2a	Nx	Mx	IB
191596	AMS-28011	AMS034	Large Cell Carcinoma	Lung	Male	Tumor	G3	T3	Nx	Mx	IIB
191597	AMS-28011	AMS035	Squamous Cell Carcinoma	Lung	Female	Tumor	G2	T2b	Nx	Mx	IIA
191598	AMS-28011	AMS036	Large Cell Carcinoma	Lung	Male	Tumor	G2	T1c	Nx	Mx	IA3
191599	AMS-28011	AMS037	Large Cell Carcinoma	Lung	Male	Tumor	G2	T2a	Nx	Mx	IB
191600	AMS-28011	AMS038	Large Cell Carcinoma	Lung	Female	Tumor	G2	T2a	Nx	Mx	IB
191601	AMS-28011	AMS039	Adenocarcinoma	Lung	Male	Tumor	G3	T2b	Nx	Mx	IIA
191602	AMS-28011	AMS040	Adenocarcinoma	Lung	Male	Tumor	G2	T2b	Nx	Mx	IIA
191603	AMS-28011	AMS041	Adenocarcinoma	Lung	Male	Tumor	G2	T2a	Nx	Mx	IB
191604	AMS-28011	AMS042	Adenocarcinoma	Lung	Male	Tumor	G2	T2b	Nx	Mx	IIA
191605	AMS-28011	AMS043	Adenocarcinoma	Lung	Male	Tumor	G3	T2a	Nx	Mx	IB
191606	AMS-28011	AMS044	Adenocarcinoma	Lung	Female	Tumor	G2	T1c	Nx	Mx	IA3
191607	AMS-28011	AMS045	Adenocarcinoma	Lung	Male	Tumor	G2	T2a	Nx	Mx	IB
191608	AMS-28011	AMS046	Adenocarcinoma	Lung	Male	Tumor	G3	T3	Nx	Mx	IIB
191609	AMS-28011	AMS047	Adenocarcinoma	Lung	Male	Tumor	G2	T2b	Nx	Mx	IIA
191610	AMS-28011	AMS048	Adenocarcinoma	Lung	Male	Tumor	G2	T2a	Nx	Mx	IB
191611	AMS-28011	AMS049	Adenocarcinoma	Lung	Male	Tumor	G3	T2b	Nx	Mx	IIA
191612	AMS-28011	AMS050	Adenocarcinoma	Lung	Male	Tumor	G2	T2a	Nx	Mx	IB
191613	AMS-28011	AMS051	Adenocarcinoma	Lung	Female	Tumor	G3	T3	Nx	Mx	IIB
191614	AMS-28011	AMS052	Adenocarcinoma	Lung	Female	Tumor	G2	T1c	Nx	Mx	IA3
191615	AMS-28011	AMS053	Adenocarcinoma	Lung	Male	Tumor	G2	T2b	Nx	Mx	IIA
191616	AMS-28011	AMS054	Adenocarcinoma	Lung	Female	Tumor	G2	T2a	Nx	Mx	IB
191617	AMS-28011	AMS055	Adenocarcinoma	Lung	Female	Tumor	G2	T2b	Nx	Mx	IIA
	T8235152	AMS056	Adenocarcinoma	Lung		Tumor					
	HP-601	AMS057		Lung		Normal					



**Table S3.** The effect of XNA on fusion detection

<b>EML4-ALK V1</b>	<b>50 copies</b>	
	no XNA	XNA
<b>Cq Rep 1</b>	31.04	31.57
<b>Cq Rep 2</b>	30.69	30.84
<b>Cq Rep 3</b>	30.86	31.14
<b>Cq Rep 4</b>	31.01	30.95
<b>Cq Rep 5</b>	31.04	31.12
<b>Cq Rep 6</b>	31.10	31.15
<b>Cq Rep 7</b>	30.99	31.36
<b>Cq Rep 8</b>	30.99	31.25
<b>Cq Rep 9</b>	31.06	31.35
<b>Cq Rep 10</b>	30.84	31.15
<b>AVG</b>	30.96	31.19
<b>SD</b>	0.13	0.21
<b>Delta Cq</b>		0.22






Figure S1. Schematic of Qfusion™ ALK, RET, or ROS1 fusion detection assay targets.



**Figure S2. Schematic of RT-qPCR workflow for Qfusion™ ALK, RET, or ROS1 fusion detection assay.**




**Figure S3. XNA blocker principal and PCR cycle**


XNA binds tightly to wild-type sequences with a perfect match at 70°C, effectively blocking DNA polymerase during the elongation step at 64°C. Moreover, XNA can bind to fusion sequences with imperfect matches, allowing DNA polymerase to displace XNA and amplify the target sequences.




EML4-ALK V1




CCDC6-RET



EML4-ALK V7



CD74-ROS1



**Figure S4. Confirmation of fusion genes by Sanger sequencing.**  
Red arrow indicates the breaking point.